They showed promising in vivo potential using adenosine deaminase acting on RNA (ADAR) on two mice models of human diseases, including mdx mouse model of DMD and spfash mouse model of Ornithine transcarbamylase (OTC) deficiency. This evidence concerns the gene OTC and hyperinsulinemic hypoglycemia, familial, 4.